Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26034080 | 0.95 | FAAH (0.47) | FAAHSLC6A5DNM1HSP90AA1CNR1 | |
| SCHEMBL24341855 | 0.88 | FAAH (0.44) | FAAHDNM1CNR1CNR2CASP2 | |
| SCHEMBL21096814 | 0.85 | FAAH (0.46) | FAAHDNM1HSP90AA1CNR1CNR2 | |
| SCHEMBL25848473 | 0.83 | NOD1 (0.40) | FAAHTLR2 | |
| SCHEMBL25839728 | 0.82 | CASP2 (0.44) | FAAHSLC6A5CASP2 | |
| SCHEMBL25849437 | 0.82 | FAAH (0.43) | FAAHDNM1HSP90AA1CNR1CNR2 | |
| SCHEMBL27817907 | 0.82 | FAAH (0.53) | FAAHSLC6A5DNM1HSP90AA1CASP2 | |
| SCHEMBL25840004 | 0.81 | KDM4E (0.33) | — | |
| SCHEMBL26035258 | 0.79 | CNR1 (0.38) | FAAHCNR1CNR2 | |
| SCHEMBL24340761 | 0.79 | FAAH (0.51) | FAAHSLC6A5DNM1HSP90AA1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | FAAH 2901/4885SLC6A5 4323/4885DNM1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.